A Phase 3 interventional study of Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321) and Visudyne in Macular Degeneration, sponsored by Bayer. Completed at 14 sites in China. Open to participants aged 50 Years and older. Per ClinicalTrials.gov, last updated 2016-11-04.
Sponsored by Bayer · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 66 studies testing aflibercept in Macular Degeneration — 2 open to participants now, 5 under way, 2 of them phase 3. aflibercept · Macular Degeneration.
Among the 66 studies testing aflibercept in Macular Degeneration, this one is the 14th largest by enrollment, is the only one that started in 2011, is one of 18 in phase 3, and was the 7th registered.
1,459 studies on the registry are indexed under Macular Degeneration; 236 are open to participants now.
Browse Macular Degeneration studies →2 of the 66 studies testing aflibercept in Macular Degeneration are open now, in 9 countries. Recruiting first, the newest first:
Amgen · Sites in United States, Czechia, Hungary and 6 more countries
Ages 50+
Tianjin Medical University Eye Hospital
Ages 50–85
By country, each count listing its studies:
aflibercept: first FDA approval 2011 (EYLEA), first EMA approval 2012. What it is approved for, and how studies give it, is on its page →
Of the 166 Macular Degeneration studies recruiting now, 117 (70%) set no upper age limit and 5 (3%) stop at 75 or younger; 19 take children under 18; 35 take healthy volunteers.
This study: 50 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
66 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 9 · Phase 2 11 · Phase 3 19 · Phase 4 27
First in 2005; this study’s year is marked. 1 started in 2011.
This study's enrollment of 304 is above the median of 56 across 985 interventional studies indexed under Macular Degeneration.
Median enrollment 55 across the 66 interventional studies. Of the 48 that completed or were terminated, 28 (58%) have results posted.
This tab as a report to print or save as PDF → With an account.
31 of 66 have an industry lead sponsor. The 10 most frequent:
Bayer is the lead sponsor of 1,674 studies on the registry; 51 are open to participants now.
Of its 214 completed or terminated interventional studies of FDA-regulated products, 132 (62%) have results posted.
30 studies in Macular Degeneration by Bayer: none open now, 1 under way, none of them phase 3. Of 29 finished, 10 (34%) have results posted.
Among the 30 studies in Macular Degeneration by Bayer, this one is the 5th largest by enrollment of the 10 interventional ones that give a count, is the only one that started in 2011, is one of 4 in phase 3, and was the 3rd registered.
Bayer’s Macular Degeneration studies by the year they started, since 2008.
2 of the studies testing aflibercept in Macular Degeneration that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07614776Phase 3AmgenA Study to Evaluate Efficacy, Safety, and Immunogenicity With ABP 938 8 mg Versus EYLEA® HD (Aflibercept) in Participants With Neovascular Age-related Macular Degeneration | 2027-07-31 |
| NCT04932980Berner AugenklinikComparison of Rapid Aflibercept and Brolucizumab T&E in wAMD | 2027-06 |
Add all 2 to your calendar (.ics) → With an account.
Among the 66 studies testing aflibercept in Macular Degeneration, from their registry updates:
Among Bayer’s 30 in Macular Degeneration:
This tab as a report to print or save as PDF → With an account.
This study will assess the efficacy and safety of intravitreally (IVT), i.e. directly into the eye administered VEGF Trap-Eye compared with photodynamic therapy (PDT) on visual function in Chinese subjects with age-related neovascular or "wet" age-related macular degeneration.
Subjects will be randomized in a 3:1 ratio to either receive VEGF Trap-Eye or PDT. Both treatment groups will receive the other treatment as a sham procedure.
Adverse events collection will be covered in Adverse Events section.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received 2.0 mg intravitreal aflibercept injection (IAI) every 4 weeks for the first 12 weeks, followed by additional 2.0 mg IAI every 8 weeks until week 48. Additionally, sham photodynamic therapy (PDT) treatments was administered as needed.
Biological: Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)
Participants received PDT as needed. Additionally, sham IAI injections was administered until week 28. Thereafter, participants received active IAI treatment until week 48.
Drug: Visudyne
Participants in the VEGF Trap-Eye group received intravitreal injections every 8 weeks following a loading phase with injections given every 4 weeks for an overall treatment period of 48 weeks. Additionally, sham PDT treatments was administered as needed.
Participants in the PDT group (Visudyne group) received Visudyne as needed. Additionally, sham IVT injections was administered until week 28. Thereafter, subjects in the PDT group received active (= no sham) VEGF Trap-Eye treatment until week 48.
Change From Baseline in Best Corrected Visual Acuity (BCVA) as Measured by ETDRS Letter Score at Week 28 - Last Observation Carried Forward (LOCF)
Visual function of the study eye was assessed using the Early Treatment Diabetic Retinopathy Study (ETDRS) Best Corrected Visual Acuity (BCVA) letter score. A higher score represents better functioning.
Time frame: Baseline and at week 28
Percentage of Participants Who Lost Fewer Than 15 Letters at Week 28 - LOCF
Visual function of the study eye was assessed using the Early Treatment Diabetic Retinopathy Study (ETDRS) Best Corrected Visual Acuity (BCVA) letter score. A higher score represents better functioning.
Time frame: At week 28
| Milestone | Aflibercept Injection (EYLEA, VEGF Trap-Eye, BAY86-5321) | PDT Treatments |
|---|---|---|
| Started | 228 | 76 |
| Completed week 28 | 216 | 71 |
| Completed | 213 | 67 |
| Not completed | 15 | 9 |
| Withdrew: Adverse event | 6 | 5 |
| Withdrew: Lost to follow-up | 0 | 1 |
| Withdrew: Protocol violation | 1 | 1 |
| Withdrew: Withdrawal by subject | 7 | 2 |
| Withdrew: Death | 1 | 0 |
Visual function of the study eye was assessed using the Early Treatment Diabetic Retinopathy Study (ETDRS) Best Corrected Visual Acuity (BCVA) letter score. A higher score represents better functioning.
| Letters correctly read | Aflibercept Injection (EYLEA, VEGF Trap-Eye, BAY86-5321) | PDT Treatments |
|---|---|---|
| Change From Baseline in Best Corrected Visual Acuity (BCVA) as Measured by ETDRS Letter Score at Week 28 - Last Observation Carried Forward (LOCF) | 14.0 ± 12.1 | 3.9 ± 14.6 |
Visual function of the study eye was assessed using the Early Treatment Diabetic Retinopathy Study (ETDRS) Best Corrected Visual Acuity (BCVA) letter score. A higher score represents better functioning.
| Percentage of participants | Aflibercept Injection (EYLEA, VEGF Trap-Eye, BAY86-5321) | PDT Treatments |
|---|---|---|
| Percentage of Participants Who Lost Fewer Than 15 Letters at Week 28 - LOCF | 98.7 | 92.1 |
Collected over From the first study drug injection until 30 days after the last study drug injection at the latest up to week 52. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Aflibercept Injection, up to Week 28 | — | 13/228 (5.7%) | 77/228 (33.8%) |
| PDT Treatments, up to Week 28 | — | 4/76 (5.3%) | 33/76 (43.4%) |
| Aflibercept Injection, From Week 28 to Week 52 | — | 5/216 (2.3%) | 18/216 (8.3%) |
| PDT Then Aflibercept Injection, From Week 28 to Week 52 | — | 3/71 (4.2%) | 9/71 (12.7%) |
| Event | Aflibercept Injection, up to Week 28 | PDT Treatments, up to Week 28 | Aflibercept Injection, From Week 28 to Week 52 | PDT Then Aflibercept Injection, From Week 28 to Week 52 |
|---|---|---|---|---|
| Visual acuity reducedEye disorders | 2/228 | 3/76 | 0/216 | 0/71 |
| Acute myocardial infarctionCardiac disorders | 0/228 | 0/76 | 0/216 | 1/71 |
| CataractEye disorders | 0/228 | 0/76 | 0/216 | 1/71 |
| Cerebral infarctionNervous system disorders | 1/228 | 0/76 | 0/216 | 1/71 |
| Diabetes mellitusMetabolism and nutrition disorders | 0/228 | 1/76 | 0/216 | 0/71 |
| Sudden hearing lossEar and labyrinth disorders | 0/228 | 0/76 | 1/216 | 0/71 |
| Vitreous haemorrhageEye disorders | 0/228 | 0/76 | 1/216 | 0/71 |
| GastritisGastrointestinal disorders | 0/228 | 0/76 | 1/216 | 0/71 |
| Cerebral ischaemiaNervous system disorders | 0/228 | 0/76 | 1/216 | 0/71 |
| HypertensionVascular disorders | 0/228 | 0/76 | 1/216 | 0/71 |
| Event | Aflibercept Injection, up to Week 28 | PDT Treatments, up to Week 28 | Aflibercept Injection, From Week 28 to Week 52 | PDT Then Aflibercept Injection, From Week 28 to Week 52 |
|---|---|---|---|---|
| Visual acuity reducedEye disorders | 16/228 | 11/76 | 6/216 | 5/71 |
| Macular fibrosisEye disorders | 27/228 | 8/76 | 6/216 | 0/71 |
| Retinal pigment epitheliopathyEye disorders | 12/228 | 8/76 | 6/216 | 1/71 |
| Conjunctival haemorrhageEye disorders | 14/228 | 4/76 | 13/216 | 4/71 |
| Retinal haemorrhageEye disorders | 9/228 | 4/76 | 0/216 | 0/71 |
| Subretinal fluidEye disorders | 2/228 | 4/76 | 2/216 | 1/71 |
| Upper respiratory tract infectionInfections and infestations | 10/228 | 4/76 | 6/216 | 0/71 |
| Intraocular pressure increasedInvestigations | 12/228 | 2/76 | 2/216 | 1/71 |
| Age, Continuous(Years) | Aflibercept Injection (EYLEA, VEGF Trap-Eye, BAY86-5321) | PDT Treatments | Total |
|---|---|---|---|
| Mean | 65.1 ± 8.8 | 64.9 ± 8.5 | 65.1 ± 8.7 |
| Sex: Female, Male(Participants) | Aflibercept Injection (EYLEA, VEGF Trap-Eye, BAY86-5321) | PDT Treatments | Total |
|---|---|---|---|
| Female | 86 | 22 | 108 |
| Male | 142 | 54 | 196 |
The record gives a start of Dec 2011, a primary completion of Mar 2014 and a completion of Aug 2014. It does not say whether these dates are actual or estimated.
Results were first posted in Mar 2015, 1 year after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2016. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Aflibercept